Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 25; no. 5; pp. 773 - 781
• Main Authors: Gruppo, Ralph, López‐Fernández, Maria‐Fernanda, Wynn, Tung T., Engl, Werner, Sharkhawy, Marlies, Tangada, Srilatha
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.09.2019; John Wiley and Sons Inc
• Subjects: Adolescent; Adult; BAX 855; Blood transfusion; Coagulation factors; extended half‐life recombinant factor VIII; Factor VIII - pharmacology; Factor VIII - therapeutic use; Factor VIII deficiency; Female; haemophilia A; Headache; Hemophilia; Hemophilia A - drug therapy; Hemostasis; Humans; Immunogenicity; Immunoglobulin G; Immunoglobulin M; Male; Middle Aged; Original; perioperative haemostasis; Perioperative Period - methods; rurioctocog alfa pegol; Surgery; TAK-660; Treatment Outcome; Young Adult; haemophilia A; rurioctocog alfa pegol; perioperative haemostasis; BAX 855; TAK-660; extended half-life recombinant factor VIII; surgery

Introduction Rurioctocog alfa pegol (BAX 855, TAK‐660) is a PEGylated, full‐length, recombinant factor VIII (rFVIII) with extended half‐life developed from unmodified rFVIII (antihaemophilic factor [recombinant]). Aim To determine the perioperative haemostatic efficacy and safety of rurioctocog alfa...